There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Relay Therapeutics (RLAY – Research Report) and Ovid Therapeutics (OVID – Research Report) with bullish sentiments.
Relay Therapeutics (RLAY)
JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Relay Therapeutics today and set a price target of $24.00. The company’s shares closed last Friday at $7.52, close to its 52-week low of $5.95.
According to TipRanks.com, Tuerkcan is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Relay Therapeutics with a $26.00 average price target, a 211.0% upside from current levels. In a report issued on November 2, TD Cowen also maintained a Buy rating on the stock.
See the top stocks recommended by analysts >>
Ovid Therapeutics (OVID)
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Ovid Therapeutics. The company’s shares closed last Friday at $3.57.
According to TipRanks.com, Baral is a 5-star analyst with an average return of
Currently, the analyst consensus on Ovid Therapeutics is a Strong Buy with an average price target of $7.00, representing a 95.0% upside. In a report issued on November 3, JonesTrading also maintained a Buy rating on the stock with a $6.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RLAY:
- Relay Therapeutics reports Q3 EPS (54c), consensus (83c)
- Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
- Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
- Relay Therapeutics price target raised to $33 from $30 at H.C. Wainwright
- Relay: Lirafugratinib data show durable response across multiple FGFR2 tumors
